
Company valuation, historical trends, and peer comparisons.
According to Evommune, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 186.88M. This represents a change of -63.37% compared to the average of 510.16M of the last 4 quarters.
The mean historical Enterprise Value of Evommune, Inc. over the last ten years is 526.10M. The current 186.88M Enterprise Value has changed -64.48% with respect to the historical average. Over the past ten years (40 quarters), EVMN's Enterprise Value was at its highest in in the June 2025 quarter at 804.45M. The Enterprise Value was at its lowest in in the March 2024 quarter at 0.
Average
526.10M
Median
730.08M
Minimum
62.71M
Maximum
785.53M
Discovering the peaks and valleys of Evommune, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 7.60%
Maximum Annual Enterprise Value = 785.53M
Minimum Annual Increase = -92.02%
Minimum Annual Enterprise Value = 62.71M
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 62.71M | -92.02% |
| 2024 | 785.53M | 7.60% |
The current Enterprise Value of Evommune, Inc. (EVMN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
526.10M
5-year avg
526.10M
10-year avg
526.10M
Evommune, Inc.’s Enterprise Value is greater than Artiva Biotherapeutics, Inc. (-87733200.00), greater than Codexis, Inc. (176.00M), less than Climb Bio, Inc. (549.37M), greater than EyePoint Pharmaceuticals, Inc. (-58293803.00), less than Fortrea Holdings Inc. (2.89B), less than Galapagos N.V. (1.84B), greater than Karyopharm Therapeutics Inc. (163.26M), less than Ligand Pharmaceuticals Incorporated (7.50B), less than OmniAb, Inc. (728.02M), less than Zymeworks Inc. (2.15B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| -87733200.00 | $203.87M | |
| 176.00M | $130.59M | |
| 549.37M | $592.17M | |
| -58293803.00 | $29.80M | |
| 2.89B | $1.99B | |
| 1.84B | $1.84B | |
| 163.26M | $2.36M | |
| 7.50B | $6.42B | |
| 728.02M | $732.77M | |
| 2.15B | $2.06B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Evommune, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Evommune, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Evommune, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Evommune, Inc. (EVMN)?
What is the 3-year average Enterprise Value for Evommune, Inc. (EVMN)?
What is the 5-year average Enterprise Value for Evommune, Inc. (EVMN)?
How does the current Enterprise Value for Evommune, Inc. (EVMN) compare to its historical average?